Luo X, Liang Y, Hou L, et al. - Researchers conducted the study for analyzing the long‐term effectiveness and safety of gonadotropin‐releasing hormone analog (GnRHa) treatment in children with idiopathic central precocious puberty (CPP). For eligible comparative and single‐arm studies, PubMed, EMBASE, and the Cochrane Library were searched. A total of 98 studies, including 5,475 individuals, were identified. Evidence shows that GnRHa treatment increases FAH and decreases BMI in girls with idiopathic CPP compared with no treatment. GnRHa treatment did not evidently raise the risk of PCOS. However, evidence regarding other key long‐term outcomes (like infertility and malignant or metabolic diseases) was considered very poor to indicate the advantages or side effects of GnRHa therapy. Additional high‐quality evidence is required before firm conclusions can be drawn.